Obstet. gynecol; 142 (6), 2023

To provide recommendations for the management of premenstrual syndrome and premenstrual dysphoric disorder, collectively referred to as premenstrual disorders, based on assessment of the evidence regarding the safety and efficacy of available treatment options. An overview of the epidemiology, pathophysi...

Texto completo

Obstet. gynecol; 142 (5), 2023

Many compounding pharmacies use the phrase “bioidentical hormone” as a marketing term to imply that these preparations are natural and, thus, safer and more effective than U.S. Food and Drug Administration (FDA)–approved menopausal medications that use bioidentical or synthetic hormones or both. Ho...

Texto completo

Obstet. gynecol; 139 (4), 2022

To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis. This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Gu...

Texto completo